期刊
HUMAN MUTATION
卷 29, 期 4, 页码 456-460出版社
WILEY-LISS
DOI: 10.1002/humu.20731
关键词
warfarin; CYP2C9; VKORC1; pharmacogenetics; pharmacogenomics; PharmGKB; SNPs; IWPC
资金
- NIGMS NIH HHS [UO1GM61374] Funding Source: Medline
PharmGKB, the pharmacogenetics and pharmacogenomics knowledge base (www.pharmgkb.org) is a publicly available online resource dedicated to the dissemination of how genetic variation leads to variation in drug responses. The goals of PharmGKB are to describe relationships between genes, drugs, and diseases, and to generate knowledge to catalyze pharmacogenetic and pharmacogenomic research. PharmGKB delivers knowledge in the form of curated literature annotations, drug pathway diagrams, and very important pharmacogene (VIP) summaries. Recently, PharmGKB has embraced a new role-broker of pharmacogenomic data for data sharing consortia. In particular, we have helped create the International Warfarin Pharmacogenetics Consortium (IWPC), which is devoted to pooling genotype and phenotype data relevant to the anticoagulant warfarin. PharmGKI3 has embraced the challenge of continuing to maintain its original mission while taking an active role in the formation of pharmacogenetic consortia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据